Uniphar Reports Double-Digit Profit Growth in H1 2025

Irish healthcare group Uniphar announced significant growth in its financial performance for the first half of 2025, reporting a double-digit increase in adjusted earnings per share. The company achieved an 8 percent organic gross profit growth and benefitted from lower finance costs, as outlined in a trading update released recently.

Uniphar’s robust performance was driven largely by its Pharma division, which also recorded double-digit organic gross profit growth. The group operates four major pharmacy chains in Ireland, including Life, Allcare, Hickey’s, and McCauley. Additionally, Uniphar has substantial divisions servicing both the wholesale sector and the pharmaceutical and medical technology markets, both domestically and internationally.

Growth Outlook and Strategic Goals

Commenting on the results, Ger Rabbette, CEO of Uniphar, expressed confidence in the company’s trajectory. He stated that the business is on track to achieve a target of €200 million in EBITDA by 2028, with at least 80 percent of this growth expected to be organic. “Uniphar has had a strong first half, achieving significant organic gross profit growth. We expect to continue this progress into the second half and meet our growth objectives for each of our three divisions for the full year,” Rabbette noted.

Looking ahead, Uniphar entered the second half of the year with strong trading momentum. The company anticipates that declining interest rates will positively impact finance costs, further supporting its growth expectations. Additionally, Uniphar is actively managing a pipeline of acquisition opportunities to bolster its market position.

Financial Highlights and Stock Performance

As of the end of June 2025, Uniphar reported a net bank debt to EBITDA ratio of 1.9x. The company also successfully completed a €35 million share buyback program during the first half of the year. Following the announcement of these positive results, shares in Uniphar rose to £3.36 each in London, nearing its annual high of £3.46, which was reached in June. The company is listed on London’s AIM and Dublin’s Euronext, boasting a market capitalization of just under €1 billion.

The unaudited half-year update will be followed by the publication of the interim results for the six months ending June 30, 2025, scheduled for September 2, 2025.

Uniphar is among several Irish multinational companies that Enterprise Minister Peter Burke has recently engaged with to assess the effects of various factors, including the impacts of the Trump administration’s tariff policy on sectors influenced by the US economy and other markets. This ongoing dialogue underscores the company’s commitment to navigating the complexities of the current economic landscape while pursuing ambitious growth targets.